DXCM · NASDAQ · STOCK
DexCom (DXCM) Stock Analysis
$88.76
52W $54.11 – $91.96
64/100
$33.87B
34.7
1.41
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is DXCM Bullish or Bearish?
Bullish.
Innellis AI committee rates Dexcom (DXCM) Buy with a composite score of 64/100
, based on 6 analysts with 67% agreement.
Last updated August 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +10.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -9.02 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 36.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 36.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 17, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 22%
of 192 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 36.2% shows genuine earnings power backing the valuation
− P/E of 34.5 is moderate-to-rich
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 79.4% YoY
Technical Analyst
bullish
68
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Weekly RSI at 77 -- overbought on the larger timeframe too
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 36.4% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 20 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 63.3 to 64.0.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: score 64->68 (+4); +1 bullish signal(s).
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-08-16 to 2026-08-17 (1 day apart).
Technical Analysis
RSI (14)
69.1
Neutral
MACD Histogram
0.938
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$84.34
Resistance
$89.93
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$87.35
Above
EMA 21
$82.73
Above
EMA 50
$77.32
Above
EMA 200
$72.05
Above
Fundamental Analysis
Valuation
40
Growth
95
Profitability
100
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio
34.7×
P/B Ratio
13.14×
PEG Ratio
0.45
Dividend Yield
0.00%
52W High
$91.96
52W Low
$54.11
Quality & Growth
ROE
3045.5%
ROA
1319.1%
Gross Margin
6247.3%
Operating Margin
2292.3%
Revenue Growth YoY
—
Debt / Equity
0.53
AI Fundamental Assessment
P/E ratio of 34.7 (rich relative to a 15-40x range); Price-to-book of 13.1x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 30.5%; Return on assets of 13.2%; Net margin of 20.1%; Gross margin of 62.5%; Current ratio of 1.73 (healthy short-term liquidity); Debt-to-equity of 0.53; Free cash flow per share is positive (3.66); Most recent quarter beat estimates by 12.4%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +25.0% QoQ); Average YoY EPS growth of 45.8%; Analyst estimates rising over recent quarters
Get the Full DXCM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →